V

VYNE Therapeutics

D
VYNE
USD
0.025
(1.3405%)
Market Closed
105.000
Volume
-0.81
EPS
-
Div Yield
1.09884
P/E
27,876,360.33
Market Cap
Today
1.3405%
1 Week
5.587%
1 Month
2.162%
6 Months
-12.903%
12 Months
-52.030%
Year To Date
-19.915%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
D
DERM
-0.02
(-0.3854%)
USD
E
EOLS
0.24
(1.4806%)
USD
A
ALKS
0.52
(1.8671%)
USD
B
BLUE
-0.0046
(-0.9287%)
USD
C
CRBP
2.21
(4.4646%)
USD
M
MNK
-0.0649
(-16.0683%)
USD
T
TEVA
-0.105
(-0.5876%)
USD

Title:
VYNE Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Do you need help or have a question?
Contact Us